BMS’s Opdivo Misses Again In Glioblastoma Phase III Trial
Executive Summary
A second failure for BMS’s Opdivo in brain cancer leaves it with just one final chance in newly diagnosed disease, where the bar is lower.
You may also be interested in...
Phase III Miss In Glioblastoma Burdens VBL's Ovarian Cancer Trial
It's bad news for Israel's VBL as the company's lead gene-based biologic has failed in a critical Phase III trial in brain cancer – the pressure is on now for success with this drug candidate in ovarian cancer.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.